Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/52—Adding ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
  • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
  • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A21—BAKING; EDIBLE DOUGHS
  • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
  • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
  • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
  • A21D2/36—Vegetable material
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K2035/11—Medicinal preparations comprising living procariotic cells
  • A61K2035/115—Probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2121/00—Preparations for use in therapy

Definitions

• the invention relates to the field of food supplement manufacture and therapeutic manufacture.
• the invention relates to use of a prebiotic whole plant fibre extract from sugarcane in the diet of an individual for the prophylaxis and/or treatment of Inflammatory Bowel Disease.
• the invention also relates to a combination of the prebiotic whole plant fibre extract from sugarcane and probiotic strains, the synbiotic use of said combination in the diet of an individual, and the improved outcomes of the synbiotic approach in the prophylaxis and/or treatment of Inflammatory Bowel Disease.
• IBD Inflammatory Bowel Disease
• Gl gastrointestinal
• Colitis refers to the inflammation of the inner lining of the colon (and in some cases may involve the rectum), and there are numerous causes of colitis including Ulcerative Colitis (UC), Ischemic colitis, microscopic colitis, Crohn’s disease, and allergic reactions (including food sensitivities).
• Ulcerative Colitis UC
• Ischemic colitis Ischemic colitis
• microscopic colitis microscopic colitis
• Crohn’s disease CAD
• allergic reactions including food sensitivities
• Commonly associated inflammatory bowel effects or results of treatment can be pouchitis, diverticulitis, and the inflammation linked to antibiotic-associated diarrhea.
• IBD is now considered an emerging global disease with increasing prevalence, severity and complexity especially in western societies.
• An increasing trend is the age of onset with more young patients encountering IBD symptoms than previously recorded.
• the variation of symptoms can be significant and unpredictable in onset, trigger patterns, severity for each individual with the adverse side effects of treatment leading to the broader concerns of an individual’s mental, and social wellbeing.
• Studies are now correlating incidence of IBD to increased risks of colorectal cancer.
• a state of chronic gut inflammation involves a dysregulated mucosal immune response against commensal gut microbes in genetically susceptible individuals with impaired gut epithelial integrity.
• Several studies report dysbiosis with lower intestinal microbial diversity and altered microbial balance in colitis patients compared to healthy individuals.
• increased gut permeability owing to weakened intestinal epithelial barrier integrity is a prominent feature in colitis.
• probiotic and prebiotic components that can influence gut microbiota, strengthen intestinal barrier integrity, and modulate immune response, provide strategies to attenuate intestinal inflammation.
• Synbiotics being a combination of prebiotic and probiotic ingredients, can potentially offer prophylactic and therapeutic effects that could function synergistically to confer health benefits to the host.
• Administration of probiotics relies on an optimal viability of microbes or by-products. In search of higher viability microbes, spore-producing probiotics have become a growing research focus owing to their ability to survive the gastric transit, harsh manufacturing and storage temperatures. Additionally, many prebiotics are often purified fibres of limited chemical complexity and do not present the multiple range of glycosidic bond types that naturally occur in fruit and vegetables.
• a unique prebiotic phytonutrient fibre extract from sugarcane, manufactured to preserve the cell wall components provides a more representative cellular fibre component from plant dietary sources. While sugarcane fibre has historically been labelled as an insoluble fibre, improved fibre analysis techniques and studies into the fermentability of sugarcane fibrous matter reveals digestibility of the fibrous sub structures displaying insoluble fibre characteristics by bacteria, specifically those that reside and can function in the host colon. Providing this complex and more nature equivalent nutrient source to the microorganisms of the colon, including functional delivery of sugarcane’s characterised antioxidant bioactives (phenolics, flavonoids, and polycosanols), delivers a positive pressure on maintaining or increasing microbial diversity, rather than the reduction of diversity with limited complexity prebiotics.
• Intestinal inflammation is common in domestic animals (dogs, cats, mice, rabbits and horses) as well as captive-bred animals (chickens, cattle, goats, and fish). It is a logical conclusion that these animals would respond to similar prophylactic treatments to reduce the inflammation state of their bowels and result in similar health improvements for companion animals and deliver improved quality of life and economic benefits to industry.
• An alternative objection of the invention is to provide use of a prebiotic whole plant fibre extract from sugarcane in the diet of an individual for the ameliorating the effects of Inflammatory Bowel Disease.
• a further alternative object of the invention is to provide a synergistic combination of a prebiotic whole plant fibre extract from sugarcane and probiotics that ameliorates the symptoms of Inflammatory Bowel Disease, as a long-term prophylactic treatment by inclusion into the regular diet.
• An even further alternative objection of the invention is to provide a synergistic combination of a prebiotic whole plant fibre extract from sugarcane and probiotics that ameliorates the inflammatory states of Inflammatory Bowel Disease, as a long-term prophylactic treatment by inclusion into the regular diet.
• the present invention is directed to use of a prebiotic whole plant fibre extract from sugarcane in the diet of an individual for the prophylaxis and/or treatment of inflammatory bowel disease.
• the invention is also directed to a combination of the prebiotic whole plant fibre extract from sugarcane and probiotic strains, and the synbiotic use of said combination in the diet of an individual for the prophylaxis and/or treatment of inflammatory bowel disease.
• a prebiotic phytonutrient fibre material extracted from sugarcane for prophylaxis and/or treatment of the effects of inflammatory bowel disease.
• the prebiotic phytonutrient fibre material extracted from sugarcane is KfibreTM.
• a composition comprising a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one probiotic bacterial strain.
• the prebiotic phytonutrient fibre material is prepared via a process including the steps of: subjecting sugarcane to at least one wet diffusion step to separate sugars from a residual fibre material whilst maintaining nutrient content; and subjecting the residual fibre material to a rapid, low-heat drying process to retain biologically active molecules in the fibre, and to enhance the water retention properties of said residual fibre product.
• the wet diffusion step is a diffusion extraction, performed under relatively low-shear conditions.
• the wet diffusion step is performed within the temperature range 25°C to 70°C.
• composition can further comprise a pharmaceutically acceptable carrier, solvent, base or excipient.
• Sugarcane fibre prepared using the steps described above also has several advantageous properties compared to incomplete (not whole) plant fibres such as bran, psyllium husk and inulin.
• the fibre prepared from sugarcane is a true lignose, hemicellulose and cellulose combination, like the total dietary fibres found in most vegetables.
• Pectin is a significant component (about 10 %) of cell walls, and being a soluble, metabolizable fibre, could also play a role in the activity of the sugarcane fibre as a prebiotic.
• Other components of the sugarcane fibre include xylan (which is soluble) and arabinoxylan polymers.
• the sugarcane fibre can be classed as almost entirely insoluble fibre, using the standard chemical methods of classification, however, it has many of the properties of soluble fibres such as high water-binding capacity (up to 8-10 times by weight) and a prebiotic effect.
• the at least one probiotic bacterial strain can be commercially sourced from bacterial strains that are known and correlated to the reduction of chronic gut inflammation or to the support of the normal function of the gastrointestinal tract.
• the at least one probiotic bacterial strain is spore-forming, thereby providing robustness to survive and retaining viability in the colon of a host.
• the at least one probiotic bacterial strain can be heat stable to ensure viability during manufacture.
• the at least one bacterial strain can be acid stable, allowing the at least one bacterial strain to remain viable in the host colon after administration.
• the at least one probiotic bacterial strain is spore-forming heat stable and acid stable.
• the at least one probiotic bacterial strain is selected from the group consisting of: Bacillus coagulans, Lactobacillis (L plantarum, L. paracasei, L acidophilus, L casei, L.rhamnosus, L. crispatus, L. gasseri, L. reuteri, L bulgaricus), Bifidobacterium (B. longum, B. catenulatum , B. breve, B. animalis, B. bifidum), Streptococcus (S. sanguis, S. oralis, S. mitis, S. thermophilus, S. salivarius), Bacillus (B. subtilis, B.
• Lactococcus (L lactis), Enterococcus (E. faecium), Pediococcus (P. acidilactici), Propionibacterium (P. jensenii, P. freudenreichii), Peptostreptococcus (P. productus), and Saccharomyces (S. boulardii).
• a food product comprising a prebiotic phytonutrient fibre material extracted from sugarcane, for prophylaxis and/or treatment of the effects of inflammatory bowel disease.
• a food product comprising a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one probiotic bacterial strain.
• composition comprising a prebiotic phytonutrient fibre material extracted from sugarcane, for prophylaxis and/or treatment of the effects of inflammatory bowel disease.
• composition comprising a prebiotic phytonutrient fibre material extracted from sugarcane, for ameliorating the effects of inflammatory bowel disease.
• compositions for ameliorating the effects of Inflammatory Bowel Disease comprising prebiotic fibre material extracted from sugarcane, and at least one probiotic bacterial strain.
• a food product for ameliorating the effects of Inflammatory Bowel Disease; said food product comprising prebiotic fibre material extracted from sugarcane.
• a food product for ameliorating the effects of Inflammatory Bowel Disease comprising prebiotic fibre material extracted from sugarcane, and at least one probiotic bacterial strain.
• the food product can be utilized in the diet for a defined period of time for ameliorating the effects of IBD.
• the food product can be utilized in the diet over a prolonged period of time, including indefinitely, to ameliorate the effects of IBD and/or as a prophylactic for IBD.
• a prebiotic phytonutrient fibre material extracted from sugarcane in the manufacture of a therapeutic for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• a prebiotic phytonutrient fibre material extracted from sugarcane and at least one probiotic bacterial strain, in the manufacture of a therapeutic for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• a prebiotic phytonutrient fibre material extracted from sugarcane in the manufacture of a food product for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one probiotic bacterial strain in the manufacture of a food product for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• composition comprising a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one postbiotic.
• a postbiotic is a non-viable bacterial product or metabolic byproduct from probiotic microorganisms that has biologic activity in the host.
• a postbiotic is a fragment or metabolite of a probiotic.
• the composition can further comprise a pharmaceutically acceptable carrier, solvent, base or excipient.
• the at least one postbiotic can be commercially sourced. Preferably, the at least one postbiotic is sufficiently robust to survive in the colon. Alternatively, the at least one postbiotic can be heat stable to ensure viability during manufacture. In a further alternative, the at least one postbiotic can be acid stable, allowing the at least one postbiotic to remain viable in the colon after administration. In certain embodiments, the at least one postbiotic is heat stable and acid stable.
• the at least one postbiotic can be selected from the group consisting of short-chain fatty acids, antimicrobial peptides, nutrients (including amino acids and vitamins such as vitamin K and B-vitamins), carbohydrate-active enzymes.
• a food product comprising a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one postbiotic.
• compositions for ameliorating the effects of Inflammatory Bowel Disease comprising prebiotic fibre material extracted from sugarcane, and at least one postbiotic.
• a food product for ameliorating the effects of Inflammatory Bowel Disease comprising prebiotic fibre material extracted from sugarcane, and at least one postbiotic.
• the food product can be utilized in the diet for a defined period of time for ameliorating the effects of IBD.
• the food product can be utilized in the diet over a prolonged period of time, including indefinitely, to ameliorate the effects of IBD and/or as a prophylactic for IBD.
• a prebiotic phytonutrient fibre material extracted from sugarcane and at least one postbiotic, in the manufacture of a therapeutic for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• a prebiotic phytonutrient fibre material extracted from sugarcane, and at least one postbiotic in the manufacture of a food product for ameliorating the symptoms and/or inflammatory states of Inflammatory Bowel Disease, or for providing a prophylactic effect.
• a method of treating or ameliorating the effects of Inflammatory Bowel Disease in a subject comprising administering to the subject a composition provided by the second or fourteenth aspects, or a food product provided by the fourth or fifteenth aspects.
• Figure 1 is a diagrammatic representation of the groups of mice used in the comparative trials.
• Figure 2 is a graph showing the effect of the prebiotic on % body weight as an indicator of colitis-associated weight loss.
• Figure 3 is a graph showing the effect of the prebiotic on the Disease Activity Index (DAI).
• Figures 4A-4C are graphs of the effect of the prebiotic on physiological parameters. 4A: spleen weight; 4B: colon weight; 4C: colon weight:body weight ratio.
• Figure 5A is a graph showing the effect of the prebiotic on colon length.
• Figure 5B is a photograph of sample colons.
• Figure 6 shows graphs of the immunomodulatory effects of the prebiotic on IL-1 a and IL-1 b in the proximal colon and distal colon.
• Figure 7 shows graphs of the immunomodulatory effects of the prebiotic on IL-6 and IL-12 in the proximal colon and distal colon.
• Figure 8 shows graphs of the immunomodulatory effects of the prebiotic on TNF-a and IFN-g in the proximal colon and distal colon.
• Figure 9 shows graphs of the immunomodulatory effects of the prebiotic on IL-1 b, IL- 10 and IL-12 in serum.
• the current invention takes advantage of the properties of a prebiotic fibre isolate produced from sugarcane, in such a way that maximises retention and minimizes destruction of the bioactive molecules.
• the present inventors have surprisingly found that such a prebiotic fibre isolate is effective in the prophylaxis and/or treatment of inflammatory states associated with colitis. It has also been surprisingly found that combining the prebiotic fibre isolate with a probiotic or a postbiotic results in a synbiotic effect, whereby inflammatory states are reduced by more than when either prebiotic, probiotic, or postbiotic is used in isolation, and more than just the additive effect of the prebiotic and probiotic, or the prebiotic and postbiotic.
• the method of preparation of the prebiotic fibre material from sugarcane is broadly similar to that described in the international patent publication no. WO 201 1/035381 by KFSU Pty Ltd, which is incorporated herein by reference. Flowever, the method according to the present invention can be defined as having the following essential steps:
• a relatively‘gentle’ aqueous extraction step that separates the fibre from other sugarcane fractions, including the sugar fraction, without causing degradation of the fibre functionality
• the aqueous extraction step be an aqueous diffusion extraction performed at about neutral pH. It is also preferred that the drying step be a rapid vortex drying operation that can be achieved via a low temperature vortex dryer, said dryer being able to reduce the wet weight of the sugarcane material from 40-80% wet weight to less than 10% wet weight in 10-30 seconds while not heating the material to a level that would significantly damage the bio-actives in the plant material.
• the invention provides for the use of a prebiotic fibre extract from sugarcane, in the formulation of foods, diets or therapeutics that reduces the risk of development of Inflammatory Bowel Disease conditions, or which ameliorates the symptoms of those conditions.
• the invention also provides for the use of a synbiotic, namely, a prebiotic fibre extract from sugarcane combined with selected probiotics or postbiotics, in the formulation of foods, diets or therapeutics that reduces the risk of development of Inflammatory Bowel Disease conditions, or which ameliorates the symptoms of those conditions.
• a synbiotic namely, a prebiotic fibre extract from sugarcane combined with selected probiotics or postbiotics
• the synbiotic combination has a number of advantages over other fibre sources and food, including that:
• fibre product is added as a cellular based fibre supplement to a subject’s diet
• dietary fibre intake can be more easily controlled with a sterically hindered restricted rate of microbial metabolism.
• the embodiments of the invention can take a number of forms, each with at least one advantage.
• A‘synbiotic’ is a combination of prebiotic whole plant fibre extract from sugarcane and a probiotic bacterial strain or postbiotic byproduct for use in all subsequent formats, formulations and purposes.
• the synbiotic in most cases, includes but is not limited to, a combination of dry prebiotic and dry probiotic spores, lyophilized or live stabilised bacteria.
• the synbiotic can also be the combination in an aqueous solution for use in food manufacturing procedures.
• ⁇ A‘carrier’ is a palatable substrate for the sugarcane fibre, which may or may not contain protein or other nutrients.
• the carrier can be in a solid or liquid form, including but not limited to: fruit extracts, broths, purees, dairy products, baked goods.
• ‘Inert filler’ is any product used to increase the bulk of fibre according to the invention to allow for ease of handling by the user.
• the filler may contain flavours or nutrients, and other dietary fibres to improve mouth feel, but does not necessarily contribute to the total benefit provided by the invention.
• ‘Pellet’ includes any compact form of the invention, including but not limited to:
• a synbiotic according to the invention is pressed into a pellet or added to a flavouring medium and pressed into a pellet. Due to the inherent stability of the prebiotic and selected probiotics, the synbiotic pellets are prepared at a formulation level such that the dose may be varied according to a patient’s requirements to reduce the symptoms of Inflammatory Bowel Disease without incurring negative effects.
• Example 2
• a synbiotic is mixed with a flavoured drink (for example a non-acidic fruit juice or milk) and pasteurised for sterility (1 -5 g per 100-250 ml_).
• a drink prepared in this manner is a convenient, ready-to-consume product for the amelioration of chronic IBD symptoms.
• a supplement is prepared as an easy-to-measure powder with or without flavours, stabilisers and inert filler, formulated specifically to be combined with water.
• a synbiotic can be mixed with a dry flavour component and an inert filler to form easy-to-use granules.
• the dose (1 -5g) can be in a convenient single-serve sachet or in a multi-dose bulk pack.
• the resultant supplement is best suited to allow reduced meal size, as the granules can be mixed with water (thereby allowing less food to be consumed each meal).
• a synbiotic is prepared in a solid flavoured meal such as a biscuit, a bar, or a bread (baked) product (0.5-5 g per serve of ready mixed food).
• a solid flavoured meal such as a biscuit, a bar, or a bread (baked) product (0.5-5 g per serve of ready mixed food).
• Multiple biscuits, bars or bread products can be consumed by an individual to provide a specific dosing regimen and optimize compliance of the treatment. This has two advantages over other delivery systems in that it feels more like a treat for the consumer, it eliminates the need for liquid, and reduces the total volume of the stomach contents (a factor for inflammatory bowel conditions). Additionally, the increased saliva production may have a complementary effect with the synbiotic benefits.
• Prebiotic plant fibre (KfibreTM, sucrose reduced sugar cane fibre), was fed to C57BL/6J strain of inbred mice for 7 days prior to colitis induction with dextran sodium sulfate (DSS). Administration of prebiotic continued for another 7 days along with DSS. Colitis severity was assessed using Disease Activity Index (DAI). Colon samples were collected 7 days after colitis induction for histology, cytokines, myeloperoxidase (MPO) and inducible Nitric Oxide Synthase (iNOS) assay. Spleen weights, as well as colon weight/length and colon weight/body weight ratios, were calculated as macroscopic markers of inflammation. Fecal, mucosal and cecal contents were collected for metabolite, short chain fatty acids (SCFA), and microbial diversity analysis.
• DAI Disease Activity Index
• This group was fed normal chow for the duration of the trial (14 days), autoclaved tap water for the first 7 days, and then a solution of 2% DSS in water for the next 7 days to induce colitis
• This group was fed chow supplemented with Kfibre for the duration of the trial (14 days), autoclaved tap water for the first 7 days, and then a solution of 2% DSS in water for the next 7 days
• DAI disease activity index
• physiological parameters spleen weight, colon weight, colon length
• immunoassays quantification of pro-and anti-inflammatory cytokine levels
• histopathological evaluation - H&E staining, IHC analysis
• gut microbiota analysis - bacterial 16S rRNA gene sequencing metabolomics - quantification of SCFA (short chain fatty acids).
• Figure 2 shows that whilst the mice of the DSS control group (with induced colitis) exhibited increased weight loss over the period on DSS, the mice in the Kfibre group exhibited similar weight gain to the mice of the healthy control group. Therefore indicating that the prebiotic was significantly effective in preventing colitis-associated weight loss.
• DAI Disease Activity Index
• FIG. 5A illustrates that the DSS control group (within induced colitis) showed a significant reduction in colon length, in contrast to the Kfibre group, where the prebiotic significantly reduced colon shortening. Photographs of a sample colon from each group are shown in Figure 5B.
• preconditioning of mice with the prebiotic prior to DSS-induction reduced the severity of the disease symptoms compared with the control-DSS- colitic group (Group 2).
• Prebiotic fibre (Group 3) improved the DAI compared with that of DSS-colitic mice (Group 2).
• treatment with the prebiotic proved effective in preventing body weight loss and providing enhanced stool consistency and occult blood score.
• the treatment effectively improved or eliminated the macroscopic markers of inflammation.
• the prebiotic proved significantly effective in modulating pro-inflammatory cytokines.
• the prebiotic is thus effective in reducing the severity of chemically-induced colitis. Furthermore, precondition with the prebiotic prior to DSS-induced colitis, reduces the severity of symptoms. The prebiotic also displays significant immunomodulatory ability.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Mycology (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Botany (AREA)
• Molecular Biology (AREA)
• Alternative & Traditional Medicine (AREA)
• Medical Informatics (AREA)
• Biotechnology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68841796

Family Applications (1)

Country Status (6)

Cited By (25)

Families Citing this family (1)

Citations (7)

Family Cites Families (9)

• 2019
  • 2019-06-12 AU AU2019285375A patent/AU2019285375B2/en active Active
  • 2019-06-12 US US17/251,135 patent/US20210138002A1/en active Pending
  • 2019-06-12 JP JP2020569792A patent/JP7385930B2/ja active Active
  • 2019-06-12 CA CA3103831A patent/CA3103831A1/en active Pending
  • 2019-06-12 EP EP19820443.0A patent/EP3806879A4/en active Pending
  • 2019-06-12 WO PCT/AU2019/050604 patent/WO2019237152A1/en not_active Ceased

Patent Citations (7)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events